Malik Slassi

Dr. Slassi joined Bright Angel Therapeutics in early 2020 to lead the company’s chemistry efforts. He was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. Dr. Slassi has over 30 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including Oncology, Neurology, Immunology and Gastro-intestinal. Prior to founding Fluorinov, Dr. Slassi was Director and Vice President of Medicinal Chemistry and Manufacturing & Drug Development at NPS Pharmaceuticals and Cascade Therapeutics, respectively, and earlier he held management and scientific positions at Allelix Biopharmaceuticals Inc., Boehringer Ingelheim Research Inc., and Rhône Poulenc. During his career he has been involved in numerous multinational R&D collaborations including with Hoechst AG (Sanofi-Aventis), AstraZeneca, Johnson & Johnson, Forest Laboratories, GlaxoSmithKline, and Memory Pharmaceuticals. For seven years, he served on the steering committee for the multinational collaboration on the metabotropic Glutamate Receptors (mGluRs) program between NPS Pharma and AstraZeneca. Dr. Slassi has a strong track record of drug development with over 20 drug candidates advanced into late-stage preclinical and clinical development. Dr. Slassi has extensive experience in the areas of intellectual property management and scientific operations. He is an inventor with over 130 issued and published patents and patent applications, and author of more than 65 scientific and review articles published in international peer reviewed journals. Dr. Slassi holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.